FDA
-
-
-
-
-
-
-
FDA clears Gilead's Trodelvy for first-line metastatic TNBC
-
-
-
-
-
-
-
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
-
-
-
-
-
-
-
GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation
-
-
-
-
-
-
-
Gilead receives EU panel backing for Trodelvy in breast cancer treatment
-
-
-
-
-
-
-
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
-
-
-
-
-
-
-
Gilead Sciences to acquire Ouro Medicines for up to $2.2 billion
-
-
-
-
-
-
-
Truist Securities Downgrades Arcellx Inc. (ACLX) to Hold
-
326,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

